Tiger Brokers

BUZZ-Immunic jumps on interim late-stage data for multiple sclerosis drug

Reuters
Oct 22, 2024

** Shares of drug developer Immunic rise 20% to $1.86 premarket

** Co says an independent data monitoring committee has recommended continuing its late-stage trial for an experimental multiple sclerosis drug without changes

** The drug, vidofludimus calcium, is being tested in patients with multiple sclerosis, a chronic autoimmune disease that affects the central nervous system

** The committee has recommended the trial is not futile and should continue as planned after an interim analysis - IMUX

** Co expects the study to be completed in 2026

** Up to last close, stock up 3.3% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10